Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 4NIH 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 128Lymphoma 107Lymphoma, Large B-Cell, Diffuse 96Leukemia 55Burkitt Lymphoma 50Lymphoma, Non-Hodgkin 49Lymphoma, Follicular 37Lymphoma, Mantle-Cell 33Hodgkin Disease 25Retinoblastoma 16Recurrence 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, T-Cell, Peripheral 16Lymphoma, Large-Cell, Anaplastic 16Central Nervous System Neoplasms 16Neuroblastoma 15Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, B-Cell 15Sarcoma 13Rhabdomyosarcoma 12Lymphoma, B-Cell, Marginal Zone 12Neoplasms 11Medulloblastoma 11Immunoblastic Lymphadenopathy 11Sarcoma, Ewing 10Lymphoma, T-Cell 10Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 8Dendritic Cell Sarcoma, Interdigitating 8Enteropathy-Associated T-Cell Lymphoma 7

Interventions

Radiotherapy 2Vincristine 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Irinotecan 1Ifosfamide 1Gene Expression Profiling 1Filgrastim 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carboplatin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Malignant mesenchymal tumor × Vincristine × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡